<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33927394</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers.</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>348</EndPage><MedlinePgn>333-348</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-021-00487-8</ELocationID><Abstract><AbstractText>The prevailing motor neuron-centric view of amyotrophic lateral sclerosis (ALS) pathogenesis could be an important factor in the failure to identify disease-modifying therapy for this neurodegenerative disorder. Non-neuronal cells have crucial homeostatic functions within the CNS and evidence of involvement of these cells in the pathophysiology of several neurodegenerative disorders, including ALS, is accumulating. Microglia and astrocytes, in crosstalk with peripheral immune cells, can exert both neuroprotective and adverse effects, resulting in a highly nuanced range of neuronal and non-neuronal cell interactions. This Review provides an overview of the diverse roles of non-neuronal cells in relation to the pathogenesis of ALS and the emerging potential of non-neuronal cell biomarkers to advance therapeutic development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vahsen</LastName><ForeName>Bj&#xf6;rn F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-5159-5070</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-1063-3277</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansorge</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anthony</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0003-1380-6655</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowley</LastName><ForeName>Sally A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-0297-6675</Identifier><AffiliationInfo><Affiliation>James Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. kevin.talbot@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. martin.turner@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024962/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T006927/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33927394</ArticleId><ArticleId IdType="doi">10.1038/s41582-021-00487-8</ArticleId><ArticleId IdType="pii">10.1038/s41582-021-00487-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbot, K., Feneberg, E., Scaber, J., Thompson, A. G. &amp; Turner, M. R. Amyotrophic lateral sclerosis: the complex path to precision medicine. J. Neurol. 265, 2454&#x2013;2462 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30054789</ArticleId><ArticleId IdType="pmc">6182683</ArticleId><ArticleId IdType="doi">10.1007/s00415-018-8983-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi, A., van den Berg, L. H. &amp; Veldink, J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat. Rev. Neurol. 13, 96&#x2013;104 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton, A. E., Chio, A. &amp; Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17&#x2013;23 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24369373</ArticleId><ArticleId IdType="doi">10.1038/nn.3584</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId><ArticleId IdType="pmc">3202986</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59&#x2013;62 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId><ArticleId IdType="doi">10.1038/362059a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668&#x2013;1672 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18309045</ArticleId><ArticleId IdType="pmc">7116650</ArticleId><ArticleId IdType="doi">10.1126/science.1154584</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19251628</ArticleId><ArticleId IdType="pmc">4516382</ArticleId><ArticleId IdType="doi">10.1126/science.1165942</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId><ArticleId IdType="doi">10.1126/science.1134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, R. H. Jr &amp; Al-Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 1602 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, A. G. et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann. Neurol. 83, 258&#x2013;268 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29331073</ArticleId><ArticleId IdType="doi">10.1002/ana.25143</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bartheld, C. S., Bahney, J. &amp; Herculano-Houzel, S. The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J. Comp. Neurol. 524, 3865&#x2013;3895 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakel, S. &amp; Dimou, L. Glial cells and their function in the adult brain: a journey through the history of their ablation. Front. Cell Neurosci. 11, 24 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28243193</ArticleId><ArticleId IdType="pmc">5303749</ArticleId><ArticleId IdType="doi">10.3389/fncel.2017.00024</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, N. J. &amp; Lyons, D. A. Glia as architects of central nervous system formation and function. Science 362, 181&#x2013;185 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30309945</ArticleId><ArticleId IdType="pmc">6292669</ArticleId><ArticleId IdType="doi">10.1126/science.aat0473</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh, A. D., David, S. &amp; Bennett, F. C. Immune cell regulation of glia during CNS injury and disease. Nat. Rev. Neurosci. 21, 139&#x2013;152 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32042145</ArticleId><ArticleId IdType="doi">10.1038/s41583-020-0263-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelvig, D. P., Pakkenberg, H., Stark, A. K. &amp; Pakkenberg, B. Neocortical glial cell numbers in human brains. Neurobiol. Aging 29, 1754&#x2013;1762 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17544173</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.04.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Alliot, F., Godin, I. &amp; Pessac, B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res. Dev. Brain Res 117, 145&#x2013;152 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10567732</ArticleId><ArticleId IdType="doi">10.1016/S0165-3806(99)00113-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841&#x2013;845 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20966214</ArticleId><ArticleId IdType="pmc">3719181</ArticleId><ArticleId IdType="doi">10.1126/science.1194637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger, J. et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity 43, 92&#x2013;106 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26163371</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2015.06.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann, H., Hanisch, U. K., Noda, M. &amp; Verkhratsky, A. Physiology of microglia. Physiol. Rev. 91, 461&#x2013;553 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId><ArticleId IdType="doi">10.1152/physrev.00011.2010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn, A., Kirchhoff, F. &amp; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId><ArticleId IdType="doi">10.1126/science.1110647</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Q. &amp; Barres, B. A. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 18, 225&#x2013;242 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29151590</ArticleId><ArticleId IdType="doi">10.1038/nri.2017.125</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky, O. &amp; Weiner, H. L. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 19, 622&#x2013;635 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30206328</ArticleId><ArticleId IdType="pmc">7255106</ArticleId><ArticleId IdType="doi">10.1038/s41583-018-0057-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff, R. M. A polarizing question: do M1 and M2 microglia exist? Nat. Neurosci. 19, 987&#x2013;991 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27459405</ArticleId><ArticleId IdType="doi">10.1038/nn.4338</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani, A., Sica, A. &amp; Locati, M. Macrophage polarization comes of age. Immunity 23, 344&#x2013;346 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16226499</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2005.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, X. et al. Microglial and macrophage polarization-new prospects for brain repair. Nat. Rev. Neurol. 11, 56&#x2013;64 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25385337</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2014.207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashford, B. A. et al. Review: microglia in motor neuron disease. Neuropathol. Appl. Neurobiol. 47, 179&#x2013;197 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32594542</ArticleId><ArticleId IdType="doi">10.1111/nan.12640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, Y. &amp; Le, W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 53, 1181&#x2013;1194 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25598354</ArticleId><ArticleId IdType="doi">10.1007/s12035-014-9070-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry, J. D., Olschowka, J. A. &amp; O&#x2019;Banion, M. K. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation 11, 98 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24889886</ArticleId><ArticleId IdType="pmc">4060849</ArticleId><ArticleId IdType="doi">10.1186/1742-2094-11-98</ArticleId></ArticleIdList></Reference><Reference><Citation>Vass, K. &amp; Lassmann, H. Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system. Am. J. Pathol. 137, 789&#x2013;800 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2121041</ArticleId><ArticleId IdType="pmc">1877549</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna, M. &amp; Butovsky, O. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 35, 441&#x2013;468 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28226226</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-051116-052358</ArticleId><ArticleId IdType="pmc">8167938</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, M. R. et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 15, 601&#x2013;609 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurcher, N. R. et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 7, 409&#x2013;414 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25685708</ArticleId><ArticleId IdType="pmc">4310932</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2015.01.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo, G. et al. <sup>11</sup>C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 7, 1513&#x2013;1523 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32762033</ArticleId><ArticleId IdType="pmc">7480909</ArticleId><ArticleId IdType="doi">10.1002/acn3.51112</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel, J. S. et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55, 221&#x2013;235 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId><ArticleId IdType="doi">10.1002/ana.10805</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider, J. et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE 7, e39216 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22720079</ArticleId><ArticleId IdType="pmc">3375234</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0039216</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider, J. et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol. 123, 395&#x2013;407 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22210083</ArticleId><ArticleId IdType="pmc">3595560</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0932-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky, A. &amp; Nedergaard, M. Physiology of astroglia. Physiol. Rev. 98, 239&#x2013;389 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29351512</ArticleId><ArticleId IdType="doi">10.1152/physrev.00042.2016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriegstein, A. &amp; Alvarez-Buylla, A. The glial nature of embryonic and adult neural stem cells. Annu. Rev. Neurosci. 32, 149&#x2013;184 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19555289</ArticleId><ArticleId IdType="pmc">3086722</ArticleId><ArticleId IdType="doi">10.1146/annurev.neuro.051508.135600</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainchtein, I. D. &amp; Molofsky, A. V. Astrocytes and microglia: in sickness and in health. Trends Neurosci. 43, 144&#x2013;154 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32044129</ArticleId><ArticleId IdType="pmc">7472912</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2020.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian, J. L. et al. Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391&#x2013;6410 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22553043</ArticleId><ArticleId IdType="pmc">3480225</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6221-11.2012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew, M. V. &amp; Vinters, H. V. Astrocytes: biology and pathology. Acta Neuropathol. 119, 7&#x2013;35 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20012068</ArticleId><ArticleId IdType="doi">10.1007/s00401-009-0619-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28099414</ArticleId><ArticleId IdType="pmc">5404890</ArticleId><ArticleId IdType="doi">10.1038/nature21029</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, S. J. Astrocyte heterogeneity in the adult central nervous system. Front. Cell Neurosci. 12, 401 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30524236</ArticleId><ArticleId IdType="pmc">6262303</ArticleId><ArticleId IdType="doi">10.3389/fncel.2018.00401</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke, L. E. et al. Normal aging induces A1-like astrocyte reactivity. Proc. Natl Acad. Sci. USA 115, E1896&#x2013;E1905 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29437957</ArticleId><ArticleId IdType="doi">10.1073/pnas.1800165115</ArticleId><ArticleId IdType="pmc">5828643</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow, S. A. &amp; Barres, B. A. Reactive astrocytes: production, function, and therapeutic potential. Immunity 46, 957&#x2013;967 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2017.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata, T., Akiyama, H., Yamada, T. &amp; McGeer, P. L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140, 691&#x2013;707 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1347673</ArticleId><ArticleId IdType="pmc">1886170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam, O. H. et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 29, 1164&#x2013;1177.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31665631</ArticleId><ArticleId IdType="pmc">6866666</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.09.066</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer, D., Cordera, S., Cavalla, P. &amp; Migheli, A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 139, 27&#x2013;33 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId><ArticleId IdType="doi">10.1016/0022-510X(96)00073-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy, D., Kato, T. &amp; Kushner, P. D. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J. Neurosci. Res. 38, 336&#x2013;347 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7523689</ArticleId><ArticleId IdType="doi">10.1002/jnr.490380312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner, P. D., Stephenson, D. T. &amp; Wright, S. Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. J. Neuropathol. Exp. Neurol. 50, 263&#x2013;277 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2022968</ArticleId><ArticleId IdType="doi">10.1097/00005072-199105000-00008</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson, A. et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J. Neurol. Sci. 255, 17&#x2013;22 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17346749</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2007.01.057</ArticleId></ArticleIdList></Reference><Reference><Citation>Valerio-Gomes, B., Guimaraes, D. M., Szczupak, D. &amp; Lent, R. The absolute number of oligodendrocytes in the adult mouse brain. Front. Neuroanat. 12, 90 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30425626</ArticleId><ArticleId IdType="pmc">6218541</ArticleId><ArticleId IdType="doi">10.3389/fnana.2018.00090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergles, D. E. &amp; Richardson, W. D. Oligodendrocyte development and plasticity. Cold Spring Harb. Perspect. Biol. 8, a020453 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26492571</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a020453</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips, T. &amp; Rothstein, J. D. Oligodendroglia: metabolic supporters of neurons. J. Clin. Invest. 127, 3271&#x2013;3280 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28862639</ArticleId><ArticleId IdType="pmc">5669561</ArticleId><ArticleId IdType="doi">10.1172/JCI90610</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalski, J. P. &amp; Kothary, R. Oligodendrocytes in a nutshell. Front. Cell Neurosci. 9, 340 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26388730</ArticleId><ArticleId IdType="pmc">4556025</ArticleId><ArticleId IdType="doi">10.3389/fncel.2015.00340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S. Z. et al. NG2 glia regulate brain innate immunity via TGF-beta2/TGFBR2 axis. BMC Med. 17, 204 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31727112</ArticleId><ArticleId IdType="pmc">6857135</ArticleId><ArticleId IdType="doi">10.1186/s12916-019-1439-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan, M. et al. Quantitative patterns of motor cortex proteinopathy across ALS genotypes. Acta Neuropathol. Commun. 8, 98 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32616036</ArticleId><ArticleId IdType="pmc">7331195</ArticleId><ArticleId IdType="doi">10.1186/s40478-020-00961-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf, K., Masuda, T., Jordao, M. J. C. &amp; Prinz, M. Macrophages at CNS interfaces: ontogeny and function in health and disease. Nat. Rev. Neurosci. 20, 547&#x2013;562 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31358892</ArticleId><ArticleId IdType="doi">10.1038/s41583-019-0201-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz, M., Erny, D. &amp; Hagemeyer, N. Ontogeny and homeostasis of CNS myeloid cells. Nat. Immunol. 18, 385&#x2013;392 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28323268</ArticleId><ArticleId IdType="doi">10.1038/ni.3703</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea, I. et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 204, 2023&#x2013;2030 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17682068</ArticleId><ArticleId IdType="pmc">2118703</ArticleId><ArticleId IdType="doi">10.1084/jem.20070064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey, W. F., Hsu, B. L. &amp; Kimura, H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28, 254&#x2013;260 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2033653</ArticleId><ArticleId IdType="doi">10.1002/jnr.490280213</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt, B., Vajkoczy, P. &amp; Weller, R. O. The movers and shapers in immune privilege of the CNS. Nat. Immunol. 18, 123&#x2013;131 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092374</ArticleId><ArticleId IdType="doi">10.1038/ni.3666</ArticleId></ArticleIdList></Reference><Reference><Citation>Daar, A. S., Fuggle, S. V., Fabre, J. W., Ting, A. &amp; Morris, P. J. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 38, 293&#x2013;298 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6591602</ArticleId><ArticleId IdType="doi">10.1097/00007890-198409000-00019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarmin, S. J. et al. T cell receptor-induced phosphoinositide-3-kinase p110delta activity is required for T cell localization to antigenic tissue in mice. J. Clin. Invest. 118, 1154&#x2013;1164 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18259608</ArticleId><ArticleId IdType="pmc">2230659</ArticleId></ArticleIdList></Reference><Reference><Citation>David, R. et al. T-cell receptor- and CD28-induced Vav1 activity is required for the accumulation of primed T cells into antigenic tissue. Blood 113, 3696&#x2013;3705 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19060239</ArticleId><ArticleId IdType="doi">10.1182/blood-2008-09-176511</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo, S. et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of amyotrophic lateral sclerosis. Nat. Commun. 11, 1773 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32286313</ArticleId><ArticleId IdType="pmc">7156729</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-15644-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772&#x2013;1775 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId><ArticleId IdType="doi">10.1126/science.8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips, T. &amp; Rothstein, J. D. Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol. 69, 5.67.1&#x2013;5.67.21 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, B. J. &amp; Talbot, K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85, 94&#x2013;134 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18282652</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2008.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall, E. D., Oostveen, J. A. &amp; Gurney, M. E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249&#x2013;256 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1098-1136(199807)23:3&lt;249::AID-GLIA7&gt;3.0.CO;2-#</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu, M. E., Kozovska, M. &amp; Appel, S. H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57, 1282&#x2013;1289 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11591849</ArticleId><ArticleId IdType="doi">10.1212/WNL.57.7.1282</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips, T. &amp; Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 10, 253&#x2013;263 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21349440</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova, A., Lagani&#xe8;re, J., Roussel, J., Brisebois, K. &amp; Rouleau, G. A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 21, 3369&#x2013;3374 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11331366</ArticleId><ArticleId IdType="pmc">6762496</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.21-10-03369.2001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino, M. M., Schneider, C. &amp; Caroni, P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 22, 4825&#x2013;4832 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12077179</ArticleId><ArticleId IdType="pmc">6757755</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-12-04825.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. et al. Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology. Neurobiol. Dis. 29, 400&#x2013;408 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18054242</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2007.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma, D., Teuling, E., Haasdijk, E. D., De Zeeuw, C. I. &amp; Hoogenraad, C. C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 28, 2075&#x2013;2088 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18305242</ArticleId><ArticleId IdType="pmc">6671838</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5258-07.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers, D. R. et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 103, 16021&#x2013;16026 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17043238</ArticleId><ArticleId IdType="doi">10.1073/pnas.0607423103</ArticleId><ArticleId IdType="pmc">1613228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph, G. S. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429&#x2013;433 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15768029</ArticleId><ArticleId IdType="doi">10.1038/nm1205</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389&#x2013;1392 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId><ArticleId IdType="doi">10.1126/science.1123511</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, B., Zhao, W., Beers, D. R., Henkel, J. S. &amp; Appel, S. H. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 237, 147&#x2013;152 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22735487</ArticleId><ArticleId IdType="pmc">4126417</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravel, M. et al. IL-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1. J. Neurosci. 36, 1031&#x2013;1048 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26791230</ArticleId><ArticleId IdType="pmc">6601999</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0854-15.2016</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, Q. et al. Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J. Neurochem. 102, 2008&#x2013;2019 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17555556</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04677.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, W. et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 58, 231&#x2013;243 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19672969</ArticleId><ArticleId IdType="pmc">2784168</ArticleId><ArticleId IdType="doi">10.1002/glia.20919</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt, P., Yuen, E. C., Ransom, B. R. &amp; Moller, T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 48, 179&#x2013;182 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15378658</ArticleId><ArticleId IdType="doi">10.1002/glia.20062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing, G., Dequen, F., Soucy, G. &amp; Julien, J. P. Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J. Neurosci. 26, 11397&#x2013;11402 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17079668</ArticleId><ArticleId IdType="pmc">6674545</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0602-06.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner, F., Molawi, K. &amp; Zychlinsky, A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc. Natl Acad. Sci. USA 107, 13046&#x2013;13050 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20616033</ArticleId><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">2919927</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, M. D., Julien, J. P. &amp; Rivest, S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann. Neurol. 50, 630&#x2013;639 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11706969</ArticleId><ArticleId IdType="doi">10.1002/ana.1256</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu, I. M. et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385&#x2013;401 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23850290</ArticleId><ArticleId IdType="pmc">4272581</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2013.06.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M. &amp; Baloh, R. H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 106, 18809&#x2013;18814 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19833869</ArticleId><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">2762420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara, J. H. et al. MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J. Neuroinflammation 16, 196 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31666087</ArticleId><ArticleId IdType="pmc">6822373</ArticleId><ArticleId IdType="doi">10.1186/s12974-019-1589-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, W. et al. TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. Exp. Neurol. 273, 24&#x2013;35 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2015.07.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Deora, V. et al. The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia 68, 407&#x2013;421 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31596526</ArticleId><ArticleId IdType="doi">10.1002/glia.23728</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal-Lasarte, M. M., Franco, J. M., Labrador-Garrido, A., Pozo, D. &amp; Roodveldt, C. Extracellular TDP-43 aggregates target MAPK/MAK/MRK overlapping kinase (MOK) and trigger caspase-3/IL-18 signaling in microglia. FASEB J. 31, 2797&#x2013;2816 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28336525</ArticleId><ArticleId IdType="doi">10.1096/fj.201601163R</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller, K. J. et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat. Neurosci. 21, 329&#x2013;340 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29463850</ArticleId><ArticleId IdType="pmc">5857237</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0083-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Svahn, A. J. et al. Nucleo-cytoplasmic transport of TDP-43 studied in real time: impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons. Acta Neuropathol. 136, 445&#x2013;459 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29943193</ArticleId><ArticleId IdType="pmc">6096729</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1875-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli, R. C. et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron 95, 297&#x2013;308.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28669544</ArticleId><ArticleId IdType="pmc">5519492</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.05.037</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke, J. G. et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26989253</ArticleId><ArticleId IdType="pmc">5120541</ArticleId><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall, D. &amp; Baloh, R. H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Invest. 127, 3250&#x2013;3258 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28737506</ArticleId><ArticleId IdType="pmc">5669558</ArticleId><ArticleId IdType="doi">10.1172/JCI90607</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke, J. G. et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 88, 892&#x2013;901 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26637796</ArticleId><ArticleId IdType="pmc">4672384</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, J. et al. Gain of toxicity from ALS/FTD-linked repeat expansions in c9orf72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535&#x2013;550 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27112497</ArticleId><ArticleId IdType="pmc">4860075</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters, O. M. et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88, 902&#x2013;909 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26637797</ArticleId><ArticleId IdType="pmc">4828340</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 130, 845&#x2013;861 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId><ArticleId IdType="doi">10.1007/s00401-015-1476-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Q. et al. Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Mol. Med. 12, e10919 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31858749</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi, M. H. et al. Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathol. 134, 241&#x2013;254 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28409281</ArticleId><ArticleId IdType="pmc">5508040</ArticleId><ArticleId IdType="doi">10.1007/s00401-017-1711-0</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair, K. D. et al. Congenic expression of poly-GA but not poly-PR in mice triggers selective neuron loss and interferon responses found in C9orf72 ALS. Acta Neuropathol. 140, 121&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32562018</ArticleId><ArticleId IdType="pmc">7360660</ArticleId><ArticleId IdType="doi">10.1007/s00401-020-02176-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao, Z. et al. Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nat. Commun. 10, 2906 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31266945</ArticleId><ArticleId IdType="pmc">6606620</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-10956-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S. Y. et al. C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 22, 851&#x2013;862 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31086314</ArticleId><ArticleId IdType="pmc">6800116</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0397-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. J. et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med. 24, 1136&#x2013;1142 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29942091</ArticleId><ArticleId IdType="pmc">6520050</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0071-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers, M. et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 78, 426&#x2013;438 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26044557</ArticleId><ArticleId IdType="pmc">4744979</ArticleId><ArticleId IdType="doi">10.1002/ana.24453</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry, A. et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 8, 347ra393 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 110, E4530&#x2013;E4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24170860</ArticleId><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">3839752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Q. et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat. Neurosci. 23, 615&#x2013;624 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32284607</ArticleId><ArticleId IdType="pmc">7384305</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0619-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostalski, H. et al. Astrocytes and microglia as potential contributors to the pathogenesis of C9orf72 repeat expansion-associated FTLD and ALS. Front. Neurosci. 13, 486 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31156371</ArticleId><ArticleId IdType="pmc">6529740</ArticleId><ArticleId IdType="doi">10.3389/fnins.2019.00486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka, K. et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11, 251&#x2013;253 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18246065</ArticleId><ArticleId IdType="pmc">3137510</ArticleId><ArticleId IdType="doi">10.1038/nn2047</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, Y. H., Parsadanian, A. S., Andreeva, A., Snider, W. D. &amp; Elliott, J. L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20, 660&#x2013;665 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10632595</ArticleId><ArticleId IdType="pmc">6772423</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.20-02-00660.2000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L., Gutmann, D. H. &amp; Roos, R. P. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 20, 286&#x2013;293 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20962037</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddq463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore, A. C. et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 11, 1294&#x2013;1301 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18931666</ArticleId><ArticleId IdType="pmc">2656686</ArticleId><ArticleId IdType="doi">10.1038/nn.2210</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadeas, S. T., Kraig, S. E., O&#x2019;Banion, C., Lepore, A. C. &amp; Maragakis, N. J. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc. Natl Acad. Sci. USA 108, 17803&#x2013;17808 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21969586</ArticleId><ArticleId IdType="doi">10.1073/pnas.1103141108</ArticleId><ArticleId IdType="pmc">3203804</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai, M. et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 10, 615&#x2013;622 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17435755</ArticleId><ArticleId IdType="pmc">3799799</ArticleId><ArticleId IdType="doi">10.1038/nn1876</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T. &amp; Eggan, K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 10, 608&#x2013;614 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17435754</ArticleId><ArticleId IdType="pmc">3139463</ArticleId><ArticleId IdType="doi">10.1038/nn1885</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio, F. P., Boulting, G. L., Bobrowicz, S. &amp; Eggan, K. C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3, 637&#x2013;648 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2008.09.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto, M. C. et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 3, 649&#x2013;657 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19041781</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2008.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips, A. M. et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824&#x2013;828 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21832997</ArticleId><ArticleId IdType="pmc">3170425</ArticleId><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId></ArticleIdList></Reference><Reference><Citation>Phatnani, H. P. et al. Intricate interplay between astrocytes and motor neurons in ALS. Proc. Natl Acad. Sci. USA 110, E756&#x2013;E765 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23388633</ArticleId><ArticleId IdType="doi">10.1073/pnas.1222361110</ArticleId><ArticleId IdType="pmc">3581928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo, L. et al. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134, 2627&#x2013;2641 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21908873</ArticleId><ArticleId IdType="pmc">3170534</ArticleId><ArticleId IdType="doi">10.1093/brain/awr193</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas, M. R., Johnson, D. A., Sirkis, D. W., Messing, A. &amp; Johnson, J. A. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci. 28, 13574&#x2013;13581 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19074031</ArticleId><ArticleId IdType="pmc">2866507</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4099-08.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar, M., Harlan, B. A., Killoy, K. M. &amp; Vargas, M. R. Role and therapeutic potential of astrocytes in amyotrophic lateral sclerosis. Curr. Pharm. Des. 23, 5010&#x2013;5021 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28641533</ArticleId><ArticleId IdType="pmc">5740017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka, K. &amp; Komine, O. The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 126, 31&#x2013;38 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29054467</ArticleId><ArticleId IdType="doi">10.1016/j.neures.2017.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo, F. et al. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 11, 592&#x2013;604 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25892237</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan, K. A. et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat. Commun. 11, 3753 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32719333</ArticleId><ArticleId IdType="pmc">7385161</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra, V. et al. Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow. Nat. Commun. 11, 5579 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33149111</ArticleId><ArticleId IdType="pmc">7642391</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-19177-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland, D. S. et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl Acad. Sci. USA 99, 1604&#x2013;1609 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11818550</ArticleId><ArticleId IdType="doi">10.1073/pnas.032539299</ArticleId><ArticleId IdType="pmc">122237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn, L. I. et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327&#x2013;338 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditsworth, D. et al. Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta Neuropathol. 133, 907&#x2013;922 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28357566</ArticleId><ArticleId IdType="pmc">5427168</ArticleId><ArticleId IdType="doi">10.1007/s00401-017-1698-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong, J. et al. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 32, 1917&#x2013;1926 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23714777</ArticleId><ArticleId IdType="pmc">3981181</ArticleId><ArticleId IdType="doi">10.1038/emboj.2013.122</ArticleId></ArticleIdList></Reference><Reference><Citation>Velebit, J. et al. Astrocytes with TDP-43 inclusions exhibit reduced noradrenergic cAMP and Ca<sup>2+</sup> signaling and dysregulated cell metabolism. Sci. Rep. 10, 6003 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32265469</ArticleId><ArticleId IdType="pmc">7138839</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-62864-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled, D. et al. TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Hum. Mol. Genet. 26, 1732&#x2013;1746 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28334913</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddx093</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas, F., Cortes, N., Abarzua, S., Dyrda, A. &amp; van Zundert, B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front. Cell Neurosci. 8, 24 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24570655</ArticleId><ArticleId IdType="pmc">3916762</ArticleId><ArticleId IdType="doi">10.3389/fncel.2014.00024</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. Profiling the genes affected by pathogenic TDP-43 in astrocytes. J. Neurochem. 129, 932&#x2013;939 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24447103</ArticleId><ArticleId IdType="pmc">4066372</ArticleId><ArticleId IdType="doi">10.1111/jnc.12660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi, F. et al. Reactive astrocytes secrete lcn2 to promote neuron death. Proc. Natl Acad. Sci. USA 110, 4069&#x2013;4074 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23431168</ArticleId><ArticleId IdType="doi">10.1073/pnas.1218497110</ArticleId><ArticleId IdType="pmc">3593910</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi, Y. et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain 136, 1371&#x2013;1382 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23449777</ArticleId><ArticleId IdType="doi">10.1093/brain/awt029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, L. S., Cheng, W. C. &amp; Shen, C. K. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J. Biol. Chem. 287, 27335&#x2013;27344 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22718760</ArticleId><ArticleId IdType="pmc">3431639</ArticleId><ArticleId IdType="doi">10.1074/jbc.M112.359000</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, C. et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 111, E1121&#x2013;E1129 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24616503</ArticleId><ArticleId IdType="doi">10.1073/pnas.1322641111</ArticleId><ArticleId IdType="pmc">3970502</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRocca, T. J., Mariani, A., Watkins, L. R. &amp; Link, C. D. TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes. Neurobiol. Dis. 132, 104514 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31229690</ArticleId><ArticleId IdType="pmc">6834892</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2019.104514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer, B. C. et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 119, 409&#x2013;419 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20198480</ArticleId><ArticleId IdType="pmc">2880609</ArticleId><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang, P. M. et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc. Natl Acad. Sci. USA 107, 16320&#x2013;16324 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20660762</ArticleId><ArticleId IdType="doi">10.1073/pnas.1002176107</ArticleId><ArticleId IdType="pmc">2941284</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio, A. et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc. Natl Acad. Sci. USA 110, 4697&#x2013;4702 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23401527</ArticleId><ArticleId IdType="doi">10.1073/pnas.1300398110</ArticleId><ArticleId IdType="pmc">3607024</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips, A. M. et al. Altered astrocytic expression of TDP-43 does not influence motor neuron survival. Exp. Neurol. 250, 250&#x2013;259 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24120466</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2013.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst, P. et al. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain 143, 430&#x2013;440 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32040555</ArticleId><ArticleId IdType="pmc">7009461</ArticleId><ArticleId IdType="doi">10.1093/brain/awz419</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew, J. et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151&#x2013;1154 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25977373</ArticleId><ArticleId IdType="pmc">4692360</ArticleId><ArticleId IdType="doi">10.1126/science.aaa9344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. J. et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 19, 668&#x2013;677 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26998601</ArticleId><ArticleId IdType="pmc">5138863</ArticleId><ArticleId IdType="doi">10.1038/nn.4272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew, J. et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol. Neurodegener. 14, 9 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30767771</ArticleId><ArticleId IdType="pmc">6377782</ArticleId><ArticleId IdType="doi">10.1186/s13024-019-0310-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer, K. et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc. Natl Acad. Sci. USA 111, 829&#x2013;832 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24379375</ArticleId><ArticleId IdType="doi">10.1073/pnas.1314085111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue, G. M. et al. SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nat. Commun. 8, 16063 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28677678</ArticleId><ArticleId IdType="pmc">5504286</ArticleId><ArticleId IdType="doi">10.1038/ncomms16063</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger, A. et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine 50, 274&#x2013;289 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31787569</ArticleId><ArticleId IdType="pmc">6921360</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2019.11.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, S. P. et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain 142, 586&#x2013;605 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30698736</ArticleId><ArticleId IdType="pmc">6391613</ArticleId><ArticleId IdType="doi">10.1093/brain/awy353</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, S. P. et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain 142, 3771&#x2013;3790 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31647549</ArticleId><ArticleId IdType="pmc">6906594</ArticleId><ArticleId IdType="doi">10.1093/brain/awz302</ArticleId></ArticleIdList></Reference><Reference><Citation>Fomin, V. et al. The C9ORF72 gene, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, encodes a protein that functions in control of endothelin and glutamate signaling. Mol. Cell Biol. 38, e00155-18 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30150298</ArticleId><ArticleId IdType="pmc">6206455</ArticleId><ArticleId IdType="doi">10.1128/MCB.00155-18</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcianna, A. et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine 40, 626&#x2013;635 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30711519</ArticleId><ArticleId IdType="pmc">6413467</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2018.11.067</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, A. G. et al. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat. Rev. Neurol. 12, 346&#x2013;357 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27174238</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2016.68</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, C. et al. Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology. Glia 68, 1046&#x2013;1064 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31841614</ArticleId><ArticleId IdType="doi">10.1002/glia.23761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, S. H. et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16, 571&#x2013;579 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23542689</ArticleId><ArticleId IdType="pmc">3637847</ArticleId><ArticleId IdType="doi">10.1038/nn.3357</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips, T. et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain 136, 471&#x2013;482 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23378219</ArticleId><ArticleId IdType="pmc">3572934</ArticleId><ArticleId IdType="doi">10.1093/brain/aws339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka, K. et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc. Natl Acad. Sci. USA 105, 7594&#x2013;7599 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18492803</ArticleId><ArticleId IdType="doi">10.1073/pnas.0802556105</ArticleId><ArticleId IdType="pmc">2396671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo, L. et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc. Natl Acad. Sci. USA 113, E6496&#x2013;E6505 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27688759</ArticleId><ArticleId IdType="doi">10.1073/pnas.1607496113</ArticleId><ArticleId IdType="pmc">5081600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443&#x2013;448 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22801498</ArticleId><ArticleId IdType="pmc">3408792</ArticleId><ArticleId IdType="doi">10.1038/nature11314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, S. et al. Myelin degeneration induced by mutant superoxide dismutase 1 accumulation promotes amyotrophic lateral sclerosis. Glia 67, 1910&#x2013;1921 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31290185</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, S. et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proc. Natl Acad. Sci. USA 112, E6993&#x2013;E7002 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26621731</ArticleId><ArticleId IdType="doi">10.1073/pnas.1520639112</ArticleId><ArticleId IdType="pmc">4687558</ArticleId></ArticleIdList></Reference><Reference><Citation>Livesey, M. R. et al. Maturation and electrophysiological properties of human pluripotent stem cell-derived oligodendrocytes. Stem Cell 34, 1040&#x2013;1053 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2273</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky, O. et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 122, 3063&#x2013;3087 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22863620</ArticleId><ArticleId IdType="pmc">3428086</ArticleId><ArticleId IdType="doi">10.1172/JCI62636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, W. et al. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 74, 677&#x2013;685 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28437540</ArticleId><ArticleId IdType="pmc">5822209</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, Y. et al. Increased activation ability of monocytes from ALS patients. Exp. Neurol. 328, 113259 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32105709</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2020.113259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler, L. et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 132, 391&#x2013;411 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId><ArticleId IdType="doi">10.1007/s00401-016-1548-y</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley, M. E. et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature 585, 96&#x2013;101 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32814898</ArticleId><ArticleId IdType="pmc">7484469</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, L. et al. Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer A&#x3b2; peptides. Circ. Res. 121, 258&#x2013;269 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28515043</ArticleId><ArticleId IdType="pmc">5522360</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.311054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu, I. M. et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl Acad. Sci. USA 105, 17913&#x2013;17918 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18997009</ArticleId><ArticleId IdType="doi">10.1073/pnas.0804610105</ArticleId><ArticleId IdType="pmc">2581614</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers, D. R., Henkel, J. S., Zhao, W., Wang, J. &amp; Appel, S. H. CD4<sup>+</sup> T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl Acad. Sci. USA 105, 15558&#x2013;15563 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18809917</ArticleId><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">2547419</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers, D. R. et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134, 1293&#x2013;1314 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21596768</ArticleId><ArticleId IdType="pmc">3097891</ArticleId><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, W., Beers, D. R., Liao, B., Henkel, J. S. &amp; Appel, S. H. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol. Dis. 48, 418&#x2013;428 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22820142</ArticleId><ArticleId IdType="pmc">3897268</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2012.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers, D. R. et al. ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2, e89530 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28289705</ArticleId><ArticleId IdType="pmc">5333967</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.89530</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel, J. S. et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 5, 64&#x2013;79 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23143995</ArticleId><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean, R. K. et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 75, 681&#x2013;689 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29507931</ArticleId><ArticleId IdType="pmc">5885208</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId></ArticleIdList></Reference><Reference><Citation>Komine, O. et al. Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes. Cell Death Differ. 25, 2130&#x2013;2146 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29568058</ArticleId><ArticleId IdType="pmc">6261996</ArticleId><ArticleId IdType="doi">10.1038/s41418-018-0098-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo, G. et al. Counteracting roles of MHCI and CD8<sup>+</sup> T cells in the peripheral and central nervous system of ALS SOD1(G93A) mice. Mol. Neurodegener. 13, 42 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30092791</ArticleId><ArticleId IdType="pmc">6085701</ArticleId><ArticleId IdType="doi">10.1186/s13024-018-0271-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque, E. et al. Cytotoxic CD8<sup>+</sup> T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc. Natl Acad. Sci. USA 116, 2312&#x2013;2317 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30674678</ArticleId><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">6369778</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio, A. et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci. Rep. 6, 23204 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26979938</ArticleId><ArticleId IdType="pmc">4793236</ArticleId><ArticleId IdType="doi">10.1038/srep23204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, W. et al. Immunosuppressive functions of M2 macrophages derived from iPSCs of patients with ALS and healthy controls. iScience 23, 101192 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32521508</ArticleId><ArticleId IdType="pmc">7286967</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2020.101192</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein, A. et al. Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS ONE 6, e22374 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21829620</ArticleId><ArticleId IdType="pmc">3149057</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0022374</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock, B. J. et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 74, 1446&#x2013;1454 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28973548</ArticleId><ArticleId IdType="pmc">5822195</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar, U. G. et al. A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS. Front. Neurol. 10, 400 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31139131</ArticleId><ArticleId IdType="pmc">6527847</ArticleId><ArticleId IdType="doi">10.3389/fneur.2019.00400</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber, N. &amp; Shaw, P. J. Biomarkers in amyotrophic lateral sclerosis: a review of new developments. Curr. Opin. Neurol. 33, 662&#x2013;668 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32796280</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000854</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese, A. M. et al. Chitotriosidase &#x2014; a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin. Proteom. 10, 19 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker, P. et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J. Neurol. Neurosurg. Psychiatry 89, 239&#x2013;247 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29142138</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese, A. M. et al. Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation. J. Neuroinflammation 17, 232 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32762702</ArticleId><ArticleId IdType="pmc">7412641</ArticleId><ArticleId IdType="doi">10.1186/s12974-020-01909-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, A. G. et al. CSF chitinase proteins in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 1215&#x2013;1220 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31123140</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray, E. et al. CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 7, 1296&#x2013;1306 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32666680</ArticleId><ArticleId IdType="pmc">7448184</ArticleId><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl, P. et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J. Neurol. Neurosurg. Psychiatry 90, 4&#x2013;10 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30224549</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille, B. et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry 90, 1338&#x2013;1346 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Illan-Gala, I. et al. CSF sAPP&#x3b2;, YKL-40, and NfL along the ALS-FTD spectrum. Neurology 91, e1619&#x2013;e1628 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30291183</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000006383</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh, S. et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 267, 1699&#x2013;1708 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32100123</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09761-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaur, N., Perner, C., Witte, O. W. &amp; Grosskreutz, J. The chitinases as biomarkers for amyotrophic lateral sclerosis: signals from the CNS and beyond. Front. Neurol. 11, 377 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32536900</ArticleId><ArticleId IdType="pmc">7267218</ArticleId><ArticleId IdType="doi">10.3389/fneur.2020.00377</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani, R. J., Perry, G. &amp; Smith, M. A. The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotox. Res. 12, 269&#x2013;274 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18201954</ArticleId><ArticleId IdType="doi">10.1007/BF03033910</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu, L. et al. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J. Neurol. Neurosurg. Psychiatry 91, 350&#x2013;358 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31937582</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2019-321916</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres-Benito, P. et al. YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging 10, 2367&#x2013;2382 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30215603</ArticleId><ArticleId IdType="pmc">6188478</ArticleId><ArticleId IdType="doi">10.18632/aging.101551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Xia, K., Chen, L. &amp; Fan, D. Increased interleukin-6 levels in the astrocyte-derived exosomes of sporadic amyotrophic lateral sclerosis patients. Front. Neurosci. 13, 574 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31231184</ArticleId><ArticleId IdType="pmc">6560167</ArticleId><ArticleId IdType="doi">10.3389/fnins.2019.00574</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel, J. S., Beers, D. R., Siklos, L. &amp; Appel, S. H. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell Neurosci. 31, 427&#x2013;437 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16337133</ArticleId><ArticleId IdType="doi">10.1016/j.mcn.2005.10.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, F. et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 7, 1103&#x2013;1116 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32515902</ArticleId><ArticleId IdType="pmc">7359115</ArticleId><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle, J. et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 16, 771&#x2013;774 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19236470</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, J., Yang, X., Gao, L. &amp; Zang, D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 7, e00637 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28293476</ArticleId><ArticleId IdType="pmc">5346523</ArticleId><ArticleId IdType="doi">10.1002/brb3.637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnert, S. et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 344&#x2013;350 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24575871</ArticleId><ArticleId IdType="doi">10.3109/21678421.2014.884592</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata, T. et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol. Res. 29, 772&#x2013;776 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17672928</ArticleId><ArticleId IdType="doi">10.1179/016164107X229795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilms, H. et al. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J. Neuroimmunol. 144, 139&#x2013;142 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14597108</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2003.08.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan, M. C. et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 17, 104&#x2013;118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33340024</ArticleId><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora, J. S. et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 5&#x2013;14 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>